Neurovance neurovance.com


Public lists: Pharma Startups (4732)

Neurovance is a privately held, clinical-stage pharmaceutical company focused on attention-deficit hyperactivity disorder (ADHD) and related disorders. Neurovance is developing centanafadine (CTN, formerly EB-1020) for the treatment of attention-deficit hyperactivity disorder in adult and pediatric patients. The company is based in Cambridge, Mass., and was established as a spin-off from Euthymics Bioscience in 2011.

Neurovance is a privately held, clinical-stage pharmaceutical company focused on attention-deficit hyperactivity disorder (ADHD) and related disorders. Neurovance is developing centanafadine (CTN, formerly EB-1020) for the treatment of attention-defi...Show all

Company (Acquired)

Phone: 617-758-0300

Fax:

43 Thorndike Street
Suite S1-3
Cambridge, 02141
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Neurovance $35M Mar 2, 2017

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Neurovance Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 7 investors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Crystalline compounds Jun 01, 2017 Jan 02, 2018 Patent
Methods of treating fragile x associated disorders, adhd, and autism spectrum disorder Dec 09, 2014 Dec 12, 2017 Patent
1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders Nov 01, 2015 Aug 22, 2017 Patent
Crystalline compounds Jun 17, 2016 Jul 18, 2017 Patent
1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders Sep 23, 2014 Dec 08, 2015 Patent
See all 11 patents